(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Description

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

Conditions

Uveal Melanoma

Talk to us

Study Overview

On this page

Study Details

Study overview

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Condition
Uveal Melanoma
Intervention / Treatment

-

Contacts and Locations

Scottsdale

HonorHealth Research Institute, Scottsdale, Arizona, United States, 85258

La Jolla

Moores Cancer Center, La Jolla, California, United States, 92093

Los Angeles

UCLA Medical Center, Los Angeles, California, United States, 90024

Palo Alto

Stanford Cancer Institute, Palo Alto, California, United States, 94305

Denver

Sarah Cannon Research Institute, Denver, Colorado, United States, 80218

Miami

University of Miami, Miami, Florida, United States, 33146

Grand Rapids

The Cancer and Hematology Centers, Grand Rapids, Michigan, United States, 49546

Rochester

Mayo Clinic Rochester, Rochester, Minnesota, United States, 55905

Manhasset

Northwell, Manhasset, New York, United States, 11030

Durham

Duke University Health System, Durham, North Carolina, United States, 27710

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Primary localized uveal melanoma requiring either enucleation or plaque brachytherapy
  • * Able to dose orally
  • * ECOG Performance status of 0-1
  • * No other significant underlying ocular disease
  • * Adequate organ function
  • * Not pregnant/nursing or planning to become pregnant. Willing to use birth control
  • * Previous treatment with a Protein Kinase C (PKC) inhibitor
  • * Concurrent malignant disease
  • * Active HIV infection or Hep B/C
  • * Malabsorption disorder
  • * Unable to discontinue prohibited medication
  • * Impaired cardiac function or clinically significant cardiac disease
  • * Any other condition which may interfere with study interpretation or results

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

IDEAYA Biosciences,

Jasgit Sachdev, MD, STUDY_DIRECTOR, IDEAYA Biosciences

Study Record Dates

2029-01-31